Abnormal calcium handling in vascular smooth muscle cells of spontaneously hypertensive rats. 1990

T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

We have developed a system for measuring the dynamic changes in the cytoplasmic free calcium concentration [( Ca2+]i) in single vascular smooth muscle cells (VSMC) that is highly sensitive and does not cause cellular damage. Marked increases in [Ca2+]i in response to stimulation with caffeine and angiotensin II occurred in some VSMC of 4-week-old spontaneously hypertensive rats (SHR), in which the blood pressure and basal [Ca2+]i levels are not yet elevated. In 8-week-old rats, the basal [Ca2+]i level in VSMC was higher in SHR than in Wistar-Kyoto rats. Although the effects of high blood pressure on [Ca2+]i in vivo were expected to disappear during the passage culture, the [Ca2+]i in the fifth-passage cells was similar to that in the primary cells. These results suggest that the maintenance of high [Ca2+]i levels in VSMC of SHR is genetically regulated and is one of the mechanisms of hypertension in this strain, and that abnormal calcium regulation in VSMC of SHR is expressed even before overt hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
September 1992, Japanese heart journal,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
December 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
June 1990, Hypertension (Dallas, Tex. : 1979),
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
January 1984, Journal of cardiovascular pharmacology,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
December 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
February 1992, Hypertension (Dallas, Tex. : 1979),
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
January 1983, Clinical and experimental hypertension. Part A, Theory and practice,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
August 1985, Life sciences,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
March 1998, The Journal of pharmacology and experimental therapeutics,
T Sugiyama, and M Yoshizumi, and F Takaku, and Y Yazaki
October 2003, Clinical and experimental hypertension (New York, N.Y. : 1993),
Copied contents to your clipboard!